6 assets in Lennox-Gastaut Syndrome

Therapeutic assets addressing Lennox-Gastaut Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- Lennox-Gastaut Syndrome	University of Chicago	P3	BB (69)
Bexicaserin Lennox-Gastaut Syndrome	Longboard Pharmaceuticals	P2	BB (67)
Carisbamate Lennox-Gastaut Syndrome	SK Life Science, Inc.	P3	BB (64)
Soticlestat Lennox-Gastaut Syndrome	Takeda	P3	B (63)
Clemizole Lennox-Gastaut Syndrome	Epygenix	P3	B (60)
Bmb-101 Lennox-Gastaut Syndrome	Bright Minds Biosciences Pty Ltd	P2	CCC (53)